{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:13:09Z","timestamp":1790187189982,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGD24H050002"],"award-info":[{"award-number":["LTGD24H050002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Central Government Guiding Local Science and Technology Development Fund of Zhejiang Province","award":["2024ZY00008"],"award-info":[{"award-number":["2024ZY00008"]}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2025C02079"],"award-info":[{"award-number":["2025C02079"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00467-025-07023-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:43:03Z","timestamp":1762832583000},"page":"723-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study"],"prefix":"10.1007","volume":"41","author":[{"given":"Yanyan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuankuan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-3806","authenticated-orcid":false,"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"7023_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang S, Boor P (2023) IgA nephropathy. Nat Rev Dis Primers 9:67. https:\/\/doi.org\/10.1038\/s41572-023-00476-9","journal-title":"Nat Rev Dis Primers"},{"key":"7023_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12:677\u2013686. https:\/\/doi.org\/10.2215\/CJN.07420716","journal-title":"Clin J Am Soc Nephrol"},{"key":"7023_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010054","volume":"60","author":"Y Shimizu","year":"2023","unstructured":"Shimizu Y, Tomino Y, Suzuki Y (2023) IgA nephropathy: beyond the half-century. Medicina (Kaunas) 60:54. https:\/\/doi.org\/10.3390\/medicina60010054","journal-title":"Medicina (Kaunas)"},{"key":"7023_CR4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105:S117-117S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"7023_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Samuel S, Coppo R, Barratt J et al (2025) IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol 40:533\u2013569. https:\/\/doi.org\/10.1007\/s00467-024-06502-6","journal-title":"Pediatr Nephrol"},{"key":"7023_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"7023_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","volume":"82","author":"N Zhao","year":"2012","unstructured":"Zhao N, Hou P, Lv J, Moldoveanu Z et al (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790\u2013796. https:\/\/doi.org\/10.1038\/ki.2012.197","journal-title":"Kidney Int"},{"key":"7023_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000218","volume":"26","author":"G Xin","year":"2013","unstructured":"Xin G, Shi W, Xu LX, Su Y et al (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683\u2013690. https:\/\/doi.org\/10.5301\/jn.5000218","journal-title":"J Nephrol"},{"key":"7023_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","volume":"24","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA et al (2013) The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24:203\u2013215. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.04.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"7023_CR10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2012010053","volume":"23","author":"F Berthoux","year":"2012","unstructured":"Berthoux F, Suzuki H, Thibaudin L, Yanagawa H et al (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579\u20131587. https:\/\/doi.org\/10.1681\/ASN.2012010053","journal-title":"J Am Soc Nephrol"},{"key":"7023_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103291","volume":"148","author":"L Zeng","year":"2024","unstructured":"Zeng L, Yang K, Wu Y, Yu G et al (2024) Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun 148:103291. https:\/\/doi.org\/10.1016\/j.jaut.2024.103291","journal-title":"J Autoimmun"},{"key":"7023_CR12","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","volume":"16","author":"SC Yeo","year":"2023","unstructured":"Yeo SC, Barratt J (2023) The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J 16:ii9-9ii18. https:\/\/doi.org\/10.1093\/ckj\/sfad200","journal-title":"Clin Kidney J"},{"key":"7023_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","volume":"9","author":"J Zan","year":"2024","unstructured":"Zan J, Liu L, Li G, Zheng H et al (2024) Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy. Kidney Int Rep 9:1067\u20131071. https:\/\/doi.org\/10.1016\/j.ekir.2024.01.003","journal-title":"Kidney Int Rep"},{"key":"7023_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae285","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Ma J, Yao L, Fan Y (2024) Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J 17:sfae285. https:\/\/doi.org\/10.1093\/ckj\/sfae285","journal-title":"Clin Kidney J"},{"key":"7023_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540326","volume":"149","author":"L Liu","year":"2025","unstructured":"Liu L, Liu Y, Li J, Tang C et al (2025) Efficacy and safety of Telitacicept in IgA nephropathy: a retrospective, multicenter study. Nephron 149:1\u201310. https:\/\/doi.org\/10.1159\/000540326","journal-title":"Nephron"},{"key":"7023_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8:499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014","journal-title":"Kidney Int Rep"},{"key":"7023_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang S (2021) Current treatment of IgA nephropathy. Semin Immunopathol 43:717\u2013728. https:\/\/doi.org\/10.1007\/s00281-021-00888-3","journal-title":"Semin Immunopathol"},{"key":"7023_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.asn.0000103869.08096.4f","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, Melis P et al (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157\u2013163. https:\/\/doi.org\/10.1097\/01.asn.0000103869.08096.4f","journal-title":"J Am Soc Nephrol"},{"key":"7023_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ekir.2018.03.013","volume":"3","author":"A Cambier","year":"2018","unstructured":"Cambier A, Rabant M, Peuchmaur M, Hertig A et al (2018) Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep 3:916\u2013925. https:\/\/doi.org\/10.1016\/j.ekir.2018.03.013","journal-title":"Kidney Int Rep"},{"key":"7023_CR20","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F et al (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694\u20133701. https:\/\/doi.org\/10.1093\/ndt\/gfp356","journal-title":"Nephrol Dial Transplant"},{"key":"7023_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv J, Zhang H, Chen Y, Li G (2009) Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53:26\u201332. https:\/\/doi.org\/10.1053\/j.ajkd.2008.07.029","journal-title":"Am J Kidney Dis"},{"key":"7023_CR22","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1415463","journal-title":"N Engl J Med"},{"key":"7023_CR23","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327:1888\u20131898. https:\/\/doi.org\/10.1001\/jama.2022.5368","journal-title":"JAMA"},{"key":"7023_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015060.pub2","author":"A Alladin","year":"2024","unstructured":"Alladin A, Hahn D, Hodson EM, Ravani P et al (2024) Immunosuppressive therapy for IgA nephropathy in children. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD015060.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7023_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2023","unstructured":"Hou FF, Xie D, Wang J, Xu X (2023) Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open 6:e2254054. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54054","journal-title":"JAMA Netw Open"},{"key":"7023_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"RJ Hogg","year":"2015","unstructured":"Hogg RJ, Bay RC, Jennette JC, Sibley R et al (2015) Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 66:783\u2013791. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.013","journal-title":"Am J Kidney Dis"},{"key":"7023_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962.pub3","author":"DJ Tunnicliffe","year":"2024","unstructured":"Tunnicliffe DJ, Reid S, Craig JC, Samuels JA et al (2024) Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003962.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"7023_CR28","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","volume":"33","author":"Y Shima","year":"2018","unstructured":"Shima Y, Nakanishi K, Kaku Y, Ishikura K et al (2018) Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Pediatr Nephrol 33:2103\u20132112. https:\/\/doi.org\/10.1007\/s00467-018-4011-6","journal-title":"Pediatr Nephrol"},{"key":"7023_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2215\/CJN.08630910","volume":"6","author":"K Kamei","year":"2011","unstructured":"Kamei K, Nakanishi K, Ito S, Saito M et al (2011) Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol 6:1301\u20131307. https:\/\/doi.org\/10.2215\/CJN.08630910","journal-title":"Clin J Am Soc Nephrol"},{"key":"7023_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/PAP.0000000000000134","volume":"24","author":"T Al Hussain","year":"2017","unstructured":"Al Hussain T, Hussein MH, Al Mana H, Akhtar M (2017) Pathophysiology of IgA nephropathy. Adv Anat Pathol 24:56\u201362. https:\/\/doi.org\/10.1097\/PAP.0000000000000134","journal-title":"Adv Anat Pathol"},{"key":"7023_CR31","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795\u20131803. https:\/\/doi.org\/10.1681\/ASN.2011050464","journal-title":"J Am Soc Nephrol"},{"key":"7023_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A et al (2023) Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103:391\u2013402. https:\/\/doi.org\/10.1016\/j.kint.2022.09.017","journal-title":"Kidney Int"},{"key":"7023_CR33","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, Coppo R et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0","journal-title":"Lancet"},{"key":"7023_CR34","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, Wei X et al (2024) A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int 105:1306\u20131315. https:\/\/doi.org\/10.1016\/j.kint.2024.03.012","journal-title":"Kidney Int"},{"key":"7023_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, Chan TM et al (2024) A phase 2 trial of Sibeprenlimab in patients with IgA nephropathy. N Engl J Med 390:20\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2305635","journal-title":"N Engl J Med"},{"key":"7023_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf154","volume":"18","author":"Q Weng","year":"2025","unstructured":"Weng Q, Ouyang Y, Chen Z, Jin Y et al (2025) Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes. Clin Kidney J 18:sfaf154. https:\/\/doi.org\/10.1093\/ckj\/sfaf154","journal-title":"Clin Kidney J"},{"key":"7023_CR37","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ekir.2024.11.1363","volume":"10","author":"J Liu","year":"2025","unstructured":"Liu J, Han X, Jiang X, Gao X et al (2025) Efficacy and safety of Telitacicept as an add-on therapy for refractory Immunoglobulin A nephropathy or Immunoglobulin A vasculitis nephropathy in children. Kidney Int Rep 10:940\u2013943. https:\/\/doi.org\/10.1016\/j.ekir.2024.11.1363","journal-title":"Kidney Int Rep"},{"key":"7023_CR38","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","volume":"40","author":"Y Jin","year":"2025","unstructured":"Jin Y, Zhu J, Sheng A, Lin Q et al (2025) Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatr Nephrol 40:2561\u20132569. https:\/\/doi.org\/10.1007\/s00467-025-06769-3","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07023-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:02:09Z","timestamp":1769608929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7023"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07023-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Children\u2019s Hospital, Zhejiang University School of Medicine, as evidenced by the IRB approval number (2025-IRB-0268). Written informed consent was obtained from each patient or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}